Surveyed Oncologists Indicate that Avastin has Advantages over Temodar/Temodal in Increasing Overall Survival of High-Grade Glioma
A Drug That Improves Survival, When Added to Temodar/Temodal, Would Earn a 65 Percent Patient Share in the U.S. and a 30 Percent Patient Share in Europe in Newly Diagnosed Glioblastoma Multiforme, According to a New Report from Decision Resources
WALTHAM, Mass., March 9 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed oncologists identify a therapy's effect on overall survival as the attribute that most influences their prescribing decisions in high-grade glioma. Clinical data and the opinions of interviewed thought leaders indicate that Roche/Genentech/Chugai's Avastin has advantages in this attribute over Schering-Plough's Temodar/Temodal (temozolomide), the sales-leading agent in the market.
The new report entitled High-Grade Glioma: Prolonged Survival over Temozolomide Will Be Integral to Market Success finds that a therapy, when added to temozolomide, that increases median overall survival compared with temozolomide alone would earn a 65 percent patient share in the United States and a 30 percent share in Europe in newly diagnosed glioblastoma multiforme, according to surveyed U.S. and European oncologists
In 2008, Decision Resources' proprietary clinical gold standard for high-grade glioma was Avastin. Although Avastin is not formally approved for the treatment of high-grade glioma, the drug is widely prescribed off-label as a result of promising Phase II clinical trial data. Based on expert opinion, Avastin will retain clinical gold standard status through 2017, owing to its high efficacy.
"Avastin emerges as our gold standard because of its efficacy, the attribute surveyed oncologists rated as the most important in treating high-grade glioma," said Decision Resources Analyst Ramya Kollipara, Ph.D. "Because the prognosis for high-grade glioma patients is so poor, interviewed thought leaders welcome Avastin's entry into this market because of its high efficacy, despite its associated side effects and less convenient delivery."
About the Report
High-Grade Glioma: Prolonged Survival over Temozolomide Will Be Integral to Market Success is a DecisionBase 2009 report. DecisionBase 2009 is a decision-support tool that provides in-depth analysis of unmet need, physician expectations of new therapies and commercial dynamics to help pharmaceutical companies optimize their investments in drug development.
The report can be purchased by contacting Decision Resources. Members of the media may request an interview with an analyst.
About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.
About Decision Resources, Inc.
Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.
All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.
For more information, contact:
Decision Resources Decision Resources, Inc.
Christopher Comfort Elizabeth Marshall
781-296-2597 781-296-2563
[email protected] [email protected]
SOURCE Decision Resources